TD Asset Management Inc. cut its position in shares of Bristol-Myers Squibb Company (NYSE:BMY) by 10.0% in the second quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 953,676 shares of the biopharmaceutical company’s stock after selling 106,279 shares during the quarter. TD Asset Management Inc. owned approximately 0.06% of Bristol-Myers Squibb worth $53,139,000 at the end of the most recent quarter.

Several other hedge funds and other institutional investors have also recently modified their holdings of the company. Blue Chip Partners Inc. grew its holdings in shares of Bristol-Myers Squibb by 0.8% during the first quarter. Blue Chip Partners Inc. now owns 2,141 shares of the biopharmaceutical company’s stock worth $116,000 after buying an additional 17 shares in the last quarter. Keel Point LLC grew its holdings in shares of Bristol-Myers Squibb by 0.3% during the first quarter. Keel Point LLC now owns 6,286 shares of the biopharmaceutical company’s stock worth $342,000 after buying an additional 18 shares in the last quarter. Staley Capital Advisers Inc. grew its holdings in shares of Bristol-Myers Squibb by 0.3% during the first quarter. Staley Capital Advisers Inc. now owns 6,962 shares of the biopharmaceutical company’s stock worth $379,000 after buying an additional 24 shares in the last quarter. Shayne & CO. LLC grew its holdings in shares of Bristol-Myers Squibb by 0.6% during the second quarter. Shayne & CO. LLC now owns 4,041 shares of the biopharmaceutical company’s stock worth $225,000 after buying an additional 24 shares in the last quarter. Finally, Greenleaf Trust grew its holdings in shares of Bristol-Myers Squibb by 0.4% during the second quarter. Greenleaf Trust now owns 9,608 shares of the biopharmaceutical company’s stock worth $535,000 after buying an additional 39 shares in the last quarter. Institutional investors and hedge funds own 68.84% of the company’s stock.

A number of equities research analysts recently issued reports on BMY shares. UBS AG restated a “buy” rating and issued a $72.00 target price (up from $62.00) on shares of Bristol-Myers Squibb in a report on Friday, October 6th. Vetr upgraded shares of Bristol-Myers Squibb from a “hold” rating to a “buy” rating and set a $67.92 target price for the company in a report on Monday, October 9th. BMO Capital Markets restated a “sell” rating and issued a $49.00 target price on shares of Bristol-Myers Squibb in a report on Monday, September 4th. BidaskClub upgraded shares of Bristol-Myers Squibb from a “hold” rating to a “buy” rating in a report on Tuesday, June 27th. Finally, Jefferies Group LLC restated a “buy” rating and issued a $66.00 target price (up from $63.00) on shares of Bristol-Myers Squibb in a report on Thursday, August 24th. One analyst has rated the stock with a sell rating, nine have issued a hold rating and ten have issued a buy rating to the stock. The company currently has a consensus rating of “Hold” and a consensus price target of $63.21.

In related news, SVP Joseph C. Caldarella sold 9,340 shares of the stock in a transaction that occurred on Wednesday, September 6th. The stock was sold at an average price of $60.00, for a total value of $560,400.00. Following the transaction, the senior vice president now owns 46,297 shares in the company, valued at $2,777,820. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Also, Director Theodore R. Samuels II acquired 6,000 shares of the company’s stock in a transaction that occurred on Wednesday, August 2nd. The stock was purchased at an average price of $55.94 per share, for a total transaction of $335,640.00. Following the acquisition, the director now directly owns 18,000 shares of the company’s stock, valued at approximately $1,006,920. The disclosure for this purchase can be found here. Corporate insiders own 0.23% of the company’s stock.

Bristol-Myers Squibb Company (NYSE BMY) opened at 63.65 on Tuesday. The firm has a market capitalization of $104.38 billion, a PE ratio of 23.25 and a beta of 1.19. Bristol-Myers Squibb Company has a 12 month low of $46.01 and a 12 month high of $66.10. The firm’s 50-day moving average is $62.78 and its 200-day moving average is $56.98.

Bristol-Myers Squibb (NYSE:BMY) last released its quarterly earnings data on Thursday, July 27th. The biopharmaceutical company reported $0.74 EPS for the quarter, topping analysts’ consensus estimates of $0.73 by $0.01. Bristol-Myers Squibb had a return on equity of 32.33% and a net margin of 22.66%. The firm had revenue of $5.14 billion for the quarter, compared to the consensus estimate of $5.09 billion. During the same quarter in the prior year, the company posted $0.69 earnings per share. The firm’s revenue was up 5.6% on a year-over-year basis. On average, equities research analysts expect that Bristol-Myers Squibb Company will post $2.98 EPS for the current year.

The company also recently disclosed a quarterly dividend, which will be paid on Wednesday, November 1st. Investors of record on Friday, October 6th will be issued a $0.39 dividend. The ex-dividend date is Thursday, October 5th. This represents a $1.56 dividend on an annualized basis and a yield of 2.45%. Bristol-Myers Squibb’s dividend payout ratio is currently 56.73%.

TRADEMARK VIOLATION WARNING: “TD Asset Management Inc. Sells 106,279 Shares of Bristol-Myers Squibb Company (BMY)” was published by Watch List News and is the sole property of of Watch List News. If you are accessing this article on another website, it was stolen and republished in violation of US and international trademark & copyright legislation. The correct version of this article can be read at https://www.watchlistnews.com/td-asset-management-inc-sells-106279-shares-of-bristol-myers-squibb-company-bmy/1635555.html.

About Bristol-Myers Squibb

Bristol-Myers Squibb Company is engaged in the discovery, development, licensing, manufacturing, marketing, distribution and sale of biopharmaceutical products. The Company’s pharmaceutical products include chemically synthesized drugs, or small molecules, and products produced from biological processes called biologics.

Institutional Ownership by Quarter for Bristol-Myers Squibb (NYSE:BMY)

Receive News & Ratings for Bristol-Myers Squibb Company Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bristol-Myers Squibb Company and related companies with Analyst Ratings Network's FREE daily email newsletter.